Countries / Botswana
BW · BOMRA
Botswana
- Authority
- Botswana Medicines Regulatory Authority (BOMRA)
- Legal basis
- Not recorded
- Address
- Not recorded
- Website
- https://www.bomra.co.bw
- Notice channel
- https://www.bomra.co.bw/safety-alerts/Safety alerts plus regulatory notices and consultations.
- Coverage
- Captured
- Cadence
- Weekly
- On the register
- 14 recorded actions
- Last verified
- 5 September 2026
Authority Channel
Not yet open for Botswana. A regulator can claim this channel and publish directly; records published that way carry Tier 0, a rank only a regulator can create.
What we monitor, and what we cannot. One to three safety alerts a year, mostly echoes of international actions. Cadence: Weekly. Last checked 5 September 2026.
| Reference | Date | Ctry | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-BW-2026-0004 | 05 Sept 2026 | BW | Medical device categories exempt from import clearance | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2026-0003 | 02 Sept 2026 | BW | Draft regulations under the Medicines and Related Substances Act | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2026-62509537 | 14 Jul 2026 | BW | Risk of Acute Pancreatitis, Including Necrotizing and Fatal Cases, Associated with GLP‑1 Receptor Agonists and Dual GLP‑1/GIP Receptor Agonists. | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2025-84824385 | 19 Feb 2025 | BW | Tegretol Oral Suspension, limitation of use in neonates | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2025-64375315 | 19 Feb 2025 | BW | Hydrochlorothiazide – Risk Of Non Melanoma Skin Cancer ( Basal Cell Carcinoma, Squamous Cell Carcinoma) | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2024-93841841 | 16 Apr 2024 | BW | Cautionary Statement on Benylin Paediatric 100mls Cough Syrup, Batch No 329304 and 329303 | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2024-40097129 | 29 Feb 2024 | BW | Risk of serious side effects with medicines containing pseudoephedrine | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2024-39685589 | 28 Feb 2024 | BW | Safety Concern- Acute Interstitial Nephritis asscoiated with Proton Pump Inhibitorss | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2023-44412401 | 18 Apr 2023 | BW | Pholcodine consumption increases the risk of perioperative anaphylaxis to neuromuscular blocking agents | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2023-54496821 | 05 Apr 2023 | BW | Pholcodine DHCP Letter | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2023-20632138 | 13 Mar 2023 | BW | Bedaquiline-containing regimenscardiac adverse events | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2023-10424004 | 13 Mar 2023 | BW | Suspected Adverse Drug Reactions of Angiotensin 11 converting enzyme inhibitors reported to BoMRA | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2022-36212289 | 30 Mar 2022 | BW | Subcutaneous Vasculitis Associated With Metformin & Vildagliptin | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2022-76167636 | 01 Feb 2022 | BW | Covid-19 vaccines signals new | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
No action by another authority has been linked to this market.
Actions by other authorities that name this market on the notice, or that belong to a cross-border event this market also appears in. An absence here is an absence of recorded links, not a statement that no such product is on this market.